Sally Barrington

Last updated

Sally Barrington is a professor of positron emission tomography (PET) Imaging and National Institute for Health Research (NIHR) research professor at King's College London (KCL), England, United Kingdom. [1] She joined KCL in 1993.

Contents

Biography

Barrington obtained her nuclear medicine training at the Guy's and St Thomas’ Hospital London, where she was later appointed as a consultant in 1998.

Her research is focused on the study of lymphoma cancer and radiotherapy planning using PET imaging. [1] She has been involved in numerous multicentre clinical trials. She has also work experience in other clinical areas, including, but not limited to, oncology, neurology, cardiology and infection/inflammation. She co-leads the UK PET Research Network. [2]

In 2019, Barrington was awarded the British Nuclear Medicine Society (BNMS) Roll of Honour. [3] Barrington sits on the Editorial Board of Journal of Clinical Oncology; she is the chair of the National Institute for Health Research Academy Involvement Group and the Radiation Safety Committee of Guy's and St Thomas' NHS Foundation Trust. [4] She is a member of various professional organisations, including the Scientific Committee for international workshops on PET in lymphoma, European Lymphoma Institute, Administration of Radioactive Substances Advisory Committee (ARSAC), CRUK Expert Review Panel, Oncology Committee of the European Association of Nuclear Medicine, and National Cancer Research Institute (NCRI) Clinical Studies Group in Lymphoma. [5]

Selected publications

Scientific journal papers

Books edited

Book chapters

Related Research Articles

<span class="mw-page-title-main">Positron emission tomography</span> Medical imaging technique

Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. Different tracers are used for various imaging purposes, depending on the target process within the body.

<span class="mw-page-title-main">Lymphoma</span> Hematologic cancer that affects lymphocytes

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes. The name typically refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night.

A radioligand is a microscopic particle which consists of a therapeutic radioactive isotope and the cell-targeting compound - the ligand. The ligand is the target binding site, it may be on the surface of the targeted cancer cell for therapeutic purposes. Radioisotopes can occur naturally or be synthesized and produced in a cyclotron/nuclear reactor. The different types of radioisotopes include Y-90, H-3, C-11, Lu-177, Ac-225, Ra-223, In-111, I-131, I-125, etc. Thus, radioligands must be produced in special nuclear reactors for the radioisotope to remain stable. Radioligands can be used to analyze/characterize receptors, to perform binding assays, to help in diagnostic imaging, and to provide targeted cancer therapy. Radiation is a novel method of treating cancer and is effective in short distances along with being unique/personalizable and causing minimal harm to normal surrounding cells. Furthermore, radioligand binding can provide information about receptor-ligand interactions in vitro and in vivo. Choosing the right radioligand for the desired application is important. The radioligand must be radiochemically pure, stable, and demonstrate a high degree of selectivity, and high affinity for their target.

Ann Arbor staging is the staging system for lymphomas, both in Hodgkin's lymphoma and non-Hodgkin lymphoma. It was initially developed for Hodgkin's, but has some use in NHL. It has roughly the same function as TNM staging in solid tumors.

<span class="mw-page-title-main">Bone scintigraphy</span> Nuclear medicine imaging technique

A bone scan or bone scintigraphy is a nuclear medicine imaging technique used to help diagnose and assess different bone diseases. These include cancer of the bone or metastasis, location of bone inflammation and fractures, and bone infection (osteomyelitis).

A gallium scan is a type of nuclear medicine test that uses either a gallium-67 (67Ga) or gallium-68 (68Ga) radiopharmaceutical to obtain images of a specific type of tissue, or disease state of tissue. Gallium salts like gallium citrate and gallium nitrate may be used. The form of salt is not important, since it is the freely dissolved gallium ion Ga3+ which is active. Both 67Ga and 68Ga salts have similar uptake mechanisms. Gallium can also be used in other forms, for example 68Ga-PSMA is used for cancer imaging. The gamma emission of gallium-67 is imaged by a gamma camera, while the positron emission of gallium-68 is imaged by positron emission tomography (PET).

<span class="mw-page-title-main">18F-EF5</span> Chemical compound

EF5 is a nitroimidazole derivative used in oncology research. Due to its similarity in chemical structure to etanidazole, EF5 binds in cells displaying hypoxia.

Abass Alavi is an Iranian-American physician-scientist specializing in the field of molecular imaging, most notably in the imaging modality of positron emission tomography (PET). In August 1976, he was part of the team that performed the first human PET studies of the brain and whole body using the radiotracer [18F]Fluorodeoxyglucose (FDG). Alavi holds the position of Professor of Radiology and Neurology, as well as Director of Research Education in the Department of Radiology at the University of Pennsylvania. Over a career spanning five decades, he has amassed over 2,300 publications and 60,000 citations, earning an h-index of 125 and placing his publication record in the top percentile of scientists.

<span class="mw-page-title-main">Iobenguane</span> Chemical compound

Iobenguane, or MIBG, is an aralkylguanidine analog of the adrenergic neurotransmitter norepinephrine (noradrenaline), typically used as a radiopharmaceutical. It acts as a blocking agent for adrenergic neurons. When radiolabeled, it can be used in nuclear medicinal diagnostic and therapy techniques as well as in neuroendocrine chemotherapy treatments.

Nuclear medicine physicians, also called nuclear radiologists or simply nucleologists, are medical specialists that use tracers, usually radiopharmaceuticals, for diagnosis and therapy. Nuclear medicine procedures are the major clinical applications of molecular imaging and molecular therapy. In the United States, nuclear medicine physicians are certified by the American Board of Nuclear Medicine and the American Osteopathic Board of Nuclear Medicine.

<span class="mw-page-title-main">Hodgkin lymphoma</span> Type of blood and immune-system cancer

Hodgkin lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white blood cell called lymphocytes, where multinucleated Reed–Sternberg cells are present in the patient's lymph nodes. The condition was named after the English physician Thomas Hodgkin, who first described it in 1832. Symptoms may include fever, night sweats, and weight loss. Often, nonpainful enlarged lymph nodes occur in the neck, under the arm, or in the groin. Persons affected may feel tired or be itchy.

<span class="mw-page-title-main">David E. Kuhl</span> American scientist

David Edmund Kuhl was an American scientist specializing in nuclear medicine. He was well known for his pioneering work in positron emission tomography. Dr. Kuhl served as the Chief of the Division of Nuclear Medicine at the University of Michigan for 20 years and retired in June 2011.

<span class="mw-page-title-main">DOTA-TATE</span> Eight amino-acid long peptide covalently bonded to a DOTA chelator

DOTA-TATE is an eight amino acid long peptide, with a covalently bonded DOTA bifunctional chelator.

<span class="mw-page-title-main">PET-MRI</span>

Positron emission tomography–magnetic resonance imaging (PET–MRI) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging.

<span class="mw-page-title-main">Positron emission mammography</span> Imaging procedure used to detect breast cancer

Positron emission mammography (PEM) is a nuclear medicine imaging modality used to detect or characterise breast cancer. Mammography typically refers to x-ray imaging of the breast, while PEM uses an injected positron emitting isotope and a dedicated scanner to locate breast tumors. Scintimammography is another nuclear medicine breast imaging technique, however it is performed using a gamma camera. Breasts can be imaged on standard whole-body PET scanners, however dedicated PEM scanners offer advantages including improved resolution.

<span class="mw-page-title-main">FMISO</span> Chemical compound

18F-FMISO or fluoromisonidazole is a radiopharmaceutical used for PET imaging of hypoxia. It consists of a 2-nitroimidazole molecule labelled with the positron-emitter fluorine-18.

Sandro Porceddu is a head and neck radiation oncologist at Brisbane's Princess Alexandra Hospital and a Professor with the University of Queensland. He was president of the Clinical Oncologic Society of Australia (COSA) and chair of the Trials Scientific Committee of the Trans Tasman Radiation Oncology Group (TROG).

A PSMA scan is a nuclear medicine imaging technique used in the diagnosis and staging of prostate cancer. It is carried out by injection of a radiopharmaceutical with a positron or gamma emitting radionuclide and a prostate-specific membrane antigen (PSMA) targeting ligand. After injection, imaging of positron emitters such as gallium-68 (68Ga), copper-64 (64Cu), and fluorine-18 (18F) is carried out with a positron emission tomography (PET) scanner. For gamma emitters such as technetium-99m (99mTc) and indium-111 (111In) single-photon emission computed tomography (SPECT) imaging is performed with a gamma camera.

Vicky Goh is a professor, chair of clinical cancer imaging, and head of cancer imaging department at the King's College London, England, United Kingdom. She joined King's College London in 2011. She is also a consultant radiologist at Guy's and St Thomas' Hospital in London.

Theranostics, also known as theragnostics, is a technique commonly used in personalised medicine. For example in nuclear medicine, one radioactive drug is used to identify (diagnose) and a second radioactive drug is used to treat (therapy) cancerous tumors. In other words, theranostics combines radionuclide imaging and radiation therapy which targets specific biological pathways.

References

  1. 1 2 "Professor Sally Barrington". www.kcl.ac.uk. Retrieved 2020-07-22.
  2. ↑ "NCRI PET Core Lab - Structure". www.ncri-pet.org.uk. Retrieved 2020-07-22.
  3. ↑ "BNMS Roll of Honour - British Nuclear Medicine Society". www.bnms.org.uk. Retrieved 2020-07-22.
  4. ↑ "Sally Barrington - Biography - Research Portal, King's College, London". kclpure.kcl.ac.uk. Retrieved 2020-07-22.
  5. ↑ "Sally Barrington - Biography - Research Portal, King's College, London". kclpure.kcl.ac.uk. Retrieved 2020-07-22.
  6. ↑ Cheson, Bruce D.; Fisher, Richard I.; Barrington, Sally F.; Cavalli, Franco; Schwartz, Lawrence H.; Zucca, Emanuele; Lister, T. Andrew (2014-09-20). "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification". Journal of Clinical Oncology. 32 (27): 3059–3067. doi:10.1200/jco.2013.54.8800. ISSN   0732-183X. PMC   4979083 . PMID   25113753.
  7. ↑ Boellaard, Ronald; O’Doherty, Mike J; Chiti, Arturo; Krause, Bernd J. (2010-05-26). "Reply to: FDG PET and PET/CT: EANM procedure guideline for tumour PET imaging". European Journal of Nuclear Medicine and Molecular Imaging. 37 (7): 1432–1433. doi: 10.1007/s00259-010-1459-4 . ISSN   1619-7070. PMC   2886119 .
  8. ↑ Barrington, Sally F.; Mikhaeel, N. George; Kostakoglu, Lale; Meignan, Michel; Hutchings, Martin; Müeller, Stefan P.; Schwartz, Lawrence H.; Zucca, Emanuele; Fisher, Richard I.; Trotman, Judith; Hoekstra, Otto S. (2014-09-20). "Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group". Journal of Clinical Oncology. 32 (27): 3048–3058. doi:10.1200/jco.2013.53.5229. ISSN   0732-183X. PMC   5015423 . PMID   25113771.
  9. ↑ Barrington, Sally (2005-11-25). Atlas of Clinical Positron Emission Tomography. CRC Press. doi:10.1201/b13518. ISBN   978-0-429-10123-6. S2CID   70590731.
  10. ↑ Barrington, Sally. (2005). Atlas of Clinical Positron Emission Tomography 2nd Edition. Hodder Education. OCLC   746577890.
  11. ↑ Iagaru, Andrei, Sonstige. Hope, Thomas, Sonstige. Veit-Haibach, Patrick, Sonstige. (23 January 2018). PET/MRI in Oncology : Current Clinical Applications. Springer. ISBN   978-3-319-68517-5. OCLC   1021387143.{{cite book}}: CS1 maint: multiple names: authors list (link)
  12. ↑ Specht, Lena; Yahalom, Joachim, eds. (2011). Radiotherapy for Hodgkin Lymphoma. doi:10.1007/978-3-540-78944-4. ISBN   978-3-540-78455-5.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.